The estimated Net Worth of Marc E. Goldberg is at least $1.71 Million dollars as of 6 December 2013. Marc Goldberg owns over 6,861 units of CohBar Inc stock worth over $235,471 and over the last 12 years Marc sold CWBR stock worth over $1,479,128.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Marc Goldberg CWBR stock SEC Form 4 insiders trading
Marc has made over 2 trades of the CohBar Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Marc sold 6,861 units of CWBR stock worth $191,628 on 6 December 2013.
The largest trade Marc's ever made was selling 50,000 units of CohBar Inc stock on 26 November 2013 worth over $1,287,500. On average, Marc trades about 14,215 units every 3 days since 2013. As of 6 December 2013 Marc still owns at least 547,606 units of CohBar Inc stock.
You can see the complete history of Marc Goldberg stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Marc Goldberg's mailing address?
Marc's mailing address filed with the SEC is C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN, MA, 02472.
Insiders trading at CohBar Inc
Over the last 7 years, insiders at CohBar Inc have traded over $0 worth of CohBar Inc stock and bought 586,523 units worth $136,480 . The most active insiders traders include Misha Petkevich, Kenneth C Cundy, and Jon Leland Stern. On average, CohBar Inc executives and independent directors trade stock every 22 days with the average trade being worth of $9,727. The most recent stock trade was executed by David Greenwood on 1 November 2021, trading 20,000 units of CWBR stock currently worth $8,600.
What does CohBar Inc do?
cohbar (otcqx: cwbr and tsxv: cob.u) is the leader in the research and development of mitochondria-based therapeutics (mbts), an emerging class of drugs for the treatment of diseases associated with aging. mbts originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. this groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. mbts offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.
What does CohBar Inc's logo look like?
Complete history of Marc Goldberg stock trades at Enanta Pharmaceuticals Inc and CohBar Inc
CohBar Inc executives and stock owners
CohBar Inc executives and other stock owners filed with the SEC include:
-
Steven Engle,
Chief Executive Officer, Director -
Phyllis Gardner,
Independent Director -
Dr. Kenneth C. Cundy,
Chief Scientific Officer -
Jeffrey F. Biunno CPA, M.B.A., CPA, MBA,
CFO, Treasurer & Sec. -
Kenneth Cundy,
Chief Scientific Officer -
David Greenwood,
Independent Director -
Jeffrey Biunno,
Chief Financial Officer, Treasurer, Secretary -
Jon Stern,
Director -
Misha Petkevich,
Independent Director -
Albion Fitzgerald,
Independent Chairman of the Board -
Pinchas Cohen,
Independent Director -
Nir Barzilai,
Independent Director -
Jordyn Tarazi,
Director of Investor Relations -
Dr. Rohit Loomba,
Scientific Consultant -
Dr. Changhan David Lee Ph.D.,
Consultant of Mitochondrial Biology -
Dr. David Andrew Sinclair A.O., Ph.D.,
Co-Founder, Advisor & Consultant -
Dr. Joseph J. Sarret,
CEO & Director -
Simon Allen,
Chief Executive Officer -
Marc E. Goldberg,
-
Philippe Calais,
Director -
Joseph J. Sarret,
Chief Executive Officer -
John Amatruda,
Director -
Carol Nast,
Director -
Joanne Yun,
Director -
Stephanie Tozzo,
Director